Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Hoog

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
JAMA Oncology|January 18, 2024
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical TrialCynthia X Ma, Vera J Suman, Souzan Sanati, et al.
Nature Communications|January 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trialTim Kong, Alex Mabry, Maureen Highkin, et al.
Cancer Research|February 24, 2018
Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast CancersFilip Mundt, Sandeep Rajput, Shunqiang Li, et al.
Nature Communications|January 29, 2020
Microscaled proteogenomic methods for precision oncologyShankha Satpathy, Eric J Jaehnig, Karsten Krug, et al.
Cancer Discovery|August 24, 2022
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Eric J Jaehnig, Karsten Krug, et al.
Cancer Research|December 15, 2023
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell CarcinomaYige Wu, Siqi Chen, Xiaolu Yang, et al.
Nature Communications|April 26, 2017
Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenograftsKuan-Lin Huang, Shunqiang Li, Philipp Mertins, et al.
Cell Reports|August 9, 2018
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast CancerJonathan T Lei, Jieya Shao, Jin Zhang, et al.
Nature Communications|March 29, 2017
Proteogenomic integration reveals therapeutic targets in breast cancer xenograftsKuan-Lin Huang, Shunqiang Li, Philipp Mertins, et al.
Cell Reports|September 24, 2013
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenograftsShunqiang Li, Dong Shen, Jieya Shao, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
JAMA Oncology|January 18, 2024
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical TrialCynthia X Ma, Vera J Suman, Souzan Sanati, et al.
Nature Communications|January 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trialTim Kong, Alex Mabry, Maureen Highkin, et al.
Cancer Research|February 24, 2018
Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast CancersFilip Mundt, Sandeep Rajput, Shunqiang Li, et al.
Nature Communications|January 29, 2020
Microscaled proteogenomic methods for precision oncologyShankha Satpathy, Eric J Jaehnig, Karsten Krug, et al.
Cancer Discovery|August 24, 2022
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Eric J Jaehnig, Karsten Krug, et al.
Cancer Research|December 15, 2023
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell CarcinomaYige Wu, Siqi Chen, Xiaolu Yang, et al.
Nature Communications|April 26, 2017
Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenograftsKuan-Lin Huang, Shunqiang Li, Philipp Mertins, et al.
Cell Reports|August 9, 2018
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast CancerJonathan T Lei, Jieya Shao, Jin Zhang, et al.
Nature Communications|March 29, 2017
Proteogenomic integration reveals therapeutic targets in breast cancer xenograftsKuan-Lin Huang, Shunqiang Li, Philipp Mertins, et al.
Cell Reports|September 24, 2013
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenograftsShunqiang Li, Dong Shen, Jieya Shao, et al.
Pageof 5